Formula I Compounds for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy treatments for breast cancer, such as those using cyclophosphamide, 5-FU, doxorubicin, and paclitaxel, are often ineffective and associated with significant side effects, leading to a pressing need for new anticancer agents with unique activity and fewer side effects.
Innovation Solution
Development of compounds with Formula (I), which include specific alkyl, alkenyl, or alkynyl groups substituted with various functional groups, and their pharmaceutically acceptable salts, for use in treating cancer, inhibiting DNA methyltransferase 1 activity, and addressing related pathological conditions like myelodysplastic syndrome and hemaglobinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy agents (cyclophosphamide, 5-FU, doxorubicin, paclitaxel) are used, then cancer treatment is provided, but significant side effects occur and curative results are rare
Solution Approach 1:
The patent modifies the chemical structure of existing chemotherapy agents by changing molecular parameters - specifically incorporating alkyl, alkenyl, or alkynyl groups with various functional groups (carboxy, carbonyl, hydroxy, amino, etc.) at defined positions in the molecule. This structural parameter change creates novel compounds with improved therapeutic index, achieving better curative effects while reducing side effects compared to standard agents
Solution Approach 2:
The invention creates composite molecular structures by combining different functional groups and carbon chain types in specific configurations. The compounds integrate multiple functional moieties (e.g., carboxylic acid groups, carbonyl groups, hydroxyl groups, amino groups) with various carbon skeletons (saturated, unsaturated, aromatic) to achieve synergistic effects that improve both efficacy and safety profiles
2Reliability
If standard chemotherapy agents are used, then cancer treatment is provided, but the treatment is rarely curative in advanced disease
Solution Approach 1:
The patent systematically varies molecular parameters including the type of carbon chains (alkyl, alkenyl, alkynyl), the presence and position of functional groups (carboxy at R1 position, various groups at R2 position), and molecular weight to optimize the compound's interaction with cancer cells. These parameter changes result in compounds with enhanced penetrability, binding affinity, and selective toxicity, thereby improving curative effectiveness in advanced disease
3Object-affected harmful factors
If new anticancer agents with unique activity are developed, then fewer side effects are achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies local quality modification by introducing specific functional groups at specific positions in the molecular structure. The R1 position contains carboxy or carbonyl groups that provide specific biological activity, while the R2 position contains halogenated or hydroxylated groups that modulate properties locally. This targeted modification approach reduces overall molecular complexity compared to completely new molecule designs while achieving improved therapeutic profiles
Solution Approach 2:
The compound structure is segmented into distinct functional modules: the R1 carboxylic acid/ carbonyl group segment, the R2 halogenated/hydroxyl segment, and the connecting carbon chain segments. This modular segmentation allows independent optimization of each segment's contribution to efficacy and safety, simplifying the overall design process and reducing synthesis complexity compared to designing entirely new molecular architectures
Data Source
AI summary
The invention provides compounds of Formula (I):R1≡R2 (I)wherein R1 and R2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.